Ossiam Trims Holdings in Cencora, Inc. (NYSE:COR)

Ossiam decreased its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 46.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,494 shares of the company's stock after selling 3,018 shares during the period. Ossiam's holdings in Cencora were worth $785,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in COR. Norges Bank acquired a new position in Cencora during the 4th quarter worth approximately $478,309,000. Raymond James Financial Inc. bought a new position in shares of Cencora in the 4th quarter valued at $322,460,000. Invesco Ltd. boosted its holdings in shares of Cencora by 20.4% during the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after acquiring an additional 550,246 shares in the last quarter. Renaissance Technologies LLC grew its position in Cencora by 140.6% during the 4th quarter. Renaissance Technologies LLC now owns 550,700 shares of the company's stock worth $123,731,000 after acquiring an additional 321,800 shares during the last quarter. Finally, Amundi increased its holdings in Cencora by 30.8% in the 4th quarter. Amundi now owns 1,338,710 shares of the company's stock worth $318,385,000 after purchasing an additional 314,846 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Wells Fargo & Company boosted their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Bank of America lifted their target price on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Morgan Stanley set a $288.00 price objective on Cencora in a research report on Tuesday, April 15th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Finally, Evercore ISI raised their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $284.55.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the transaction, the executive vice president now directly owns 14,665 shares of the company's stock, valued at $3,934,326.20. The trade was a 21.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,223 shares of company stock worth $13,580,967 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Cencora Price Performance

NYSE COR traded up $3.66 during trading hours on Friday, hitting $286.05. The company had a trading volume of 1,815,757 shares, compared to its average volume of 1,520,659. The firm has a 50 day simple moving average of $268.09 and a 200 day simple moving average of $249.16. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $296.65. The firm has a market capitalization of $55.47 billion, a price-to-earnings ratio of 40.69, a PEG ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.